Moderna, Inc.
364 articles with Moderna, Inc.
-
Thankful for Biopharma Breakthroughs
11/26/2020
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year. -
Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
11/25/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of the European Commission’s goal to secure access to a safe and effective COVID-19 vaccine for Europe.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
-
COVID-19 Brief: WHO Recommends Against Remdesivir, Roche Ramps Up to Produce Antibodies Treatment...
11/20/2020
The World Health Organization (WHO) recommends against using Gilead Sciences' remdesivir as a treatment for COVID-19. -
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
11/17/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273,
-
Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use
11/17/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the government of the United Kingdom to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is a
-
Pfizer-BioNTech and Moderna's Vaccines Are Leading the COVID-19 Race. How Do They Compare?
11/17/2020
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures
11/16/2020
Vaccine candidate now expected to remain stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from previous estimate of 7 days
-
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
11/16/2020
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months
-
Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.
-
Swissmedic Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
11/13/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Swissmedic has started a rolling review of mRNA-1273, the Company’s vaccine candidate against COVID-19.
-
Integrating digital tools for manufacturing process development, control and data analytics brings data together in ways that enhance visibility system-wide.
-
The company said they needed 53 patients in the study to be diagnosed with COVID-19, and the trial hit that figure yesterday.
-
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
11/11/2020
Interim data from Phase 1 dose expansion cohort of mRNA-4157 in combination with pembrolizumab shared at The Society for Immunotherapy of Cancer’s Annual Meeting 2020 Data support expansion of Head and Neck Squamous Cell Carcinoma (HNSCC) cancer patient cohort Praveen Aanur, MBBS joins Moderna as Vice President, Therapeutic Area Head for Oncology Development
-
Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)
11/11/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed case accrual for the first interim analysis of the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate.
-
Moderna released interim data from the expansion cohort of its ongoing Phase I trial of its mRNA personalized cancer vaccine, mRNA-4157.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
-
Moderna to Present at Upcoming Investor Conferences in November 2020
11/2/2020
Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences: Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020 at 8:00 a.m. ET. Jefferies Virtual London Healthcare